Latest filings (excl ownership)
8-K
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200
3 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
9 May 24
424B5
Prospectus supplement for primary offering
7 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
14 Mar 24
S-8
Registration of securities for employees
19 Jan 24
EFFECT
Notice of effectiveness
19 Jan 24
424B3
Prospectus supplement
18 Jan 24
CORRESP
Correspondence with SEC
16 Jan 24
UPLOAD
Letter from SEC
16 Jan 24
S-3
Shelf registration
12 Jan 24
D
$14.43 mm in equity / options, sold $14.43 mm, 20 investors
28 Dec 23
8-K
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
11 Dec 23
8-K
Other Events
11 Dec 23
8-K
Departure of Directors or Certain Officers
7 Dec 23
8-K
Other Events
20 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
8-K
Other Events
12 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Aug 23
S-8
Registration of securities for employees
18 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
424B5
Prospectus supplement for primary offering
31 Jul 23
424B5
Prospectus supplement for primary offering
14 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
8-K
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting
5 Jun 23
8-K
Other Events
17 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
12 May 23
8-K
Departure of Directors or Certain Officers
1 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
424B5
Prospectus supplement for primary offering
27 Apr 23
Latest ownership filings
SC 13G/A
Ho William Tai-Wei
13 Feb 24
4
Corinne Epperly
8 Feb 24
4
William Tai-Wei Ho
8 Feb 24
4
Trishna Goswami
8 Feb 24
4
Kate Rochlin
8 Feb 24
4
Lawrence Lamb
8 Feb 24
4
Patrick McCall
8 Feb 24
SC 13G/A
Transcend Partners Opportunity Fund I LLC
15 Dec 23
4
Jeremy R. Graff
15 Dec 23
4
Corinne Epperly
15 Dec 23
4
Alan S. Roemer
15 Dec 23
4
William Tai-Wei Ho
15 Dec 23
4
Patrick McCall
15 Dec 23
4
Kate Rochlin
15 Dec 23
4
Trishna Goswami
15 Dec 23
4
Lawrence Lamb
15 Dec 23
4
Peter C. Brandt
15 Dec 23
SC 13G
HIRSCHMAN ORIN
15 Dec 23
SC 13D/A
BIOS Fund II, LP
15 Dec 23
3
Initial statement of insider ownership
15 Dec 23
4
Leslie W. Kreis
14 Dec 23
4
Aaron G.L. Fletcher
14 Dec 23
4
Corinne Epperly
8 Dec 23
3
Corinne Epperly
8 Dec 23
4
Jeremy R. Graff
15 Sep 23
4
Patrick McCall
28 Aug 23
4
William Tai-Wei Ho
28 Aug 23
SC 13G
Ho William Tai-Wei
11 Aug 23
SC 13G
Transcend Partners Opportunity Fund I LLC
11 Aug 23
4
EMILY FAIRBAIRN
1 Aug 23
4
Trishna Goswami
23 Jun 23
4
Patrick McCall
23 Jun 23
4
Kate Rochlin
23 Jun 23
4
Lawrence Lamb
23 Jun 23
4
William Tai-Wei Ho
23 Jun 23
4/A
William Tai-Wei Ho
23 Jun 23
4
Peter C. Brandt
16 Jun 23
4
EMILY FAIRBAIRN
16 Jun 23
4
Travis Whitfill
16 Jun 23
4
Luba Greenwood
16 Jun 23